<DOC>
	<DOCNO>NCT00733824</DOCNO>
	<brief_summary>This study evaluate safety efficacy intravenous AMD3100 add standard G-CSF mobilization regimen patient undergo autologous stem cell transplantation lymphoma . The investigator hypothesize stem cell mobilization G-CSF plus IV AMD3100 , significantly high proportion lymphoma patient collect ≥ 2 x 10E6 CD34+ cells/kg .</brief_summary>
	<brief_title>Intravenous AMD3100 Collection Autologous Peripheral Blood Stem Cells Patients With Lymphoma</brief_title>
	<detailed_description>Autologous stem cell transplantation ( ASCT ) indicate patient non-Hodgkin lymphoma ( NHL ) Hodgkin lymphoma ( HL ) primary progressive disease relapse chemotherapy-induced complete remission . For patient , patient undergo autologous transplantation , number CD34+ cell collect reliable predictor neutrophil platelet ( PLT ) engraftment transplantation . AMD3100 ( plerixafor ) promise new mobilize agent demonstrate efficacy patient NHL , HL , multiple myeloma ( MM ) . Although efficacious , subcutaneous dose AMD3100 require patient receive drug even prior apheresis , present logistical problem . Intravenous dose AMD3100 may result fast rise peripheral CD34+ cell count , drug administer day apheresis . Intravenous dosing may also increase peak CD34+ cell count , improve number CD34+ cell collect via apheresis . This Phase I/II study evaluate safety efficacy intravenous AMD3100 add standard G-CSF mobilization regimen patient undergo autologous stem cell transplantation Hodgkin non-Hodgkin lymphoma .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>Age 18 75 year Diagnosis HL NHL eligible autologous transplantation 30 day since last cycle chemotherapy ECOG performance status 0 1 The patient recover acute toxic effect prior chemotherapy WBC &gt; 3.0 X 109/l Absolute PMN count &gt; 1.5 X 109/l PLT count &gt; 100 X 109/l Serum creatinine ≤ 2.2 mg/dl AST ( SGOT ) , ALT ( SGPT ) total bilirubin &lt; 2X upper limit normal ( ULN ) Left ventricle ejection fraction &gt; 45 % ( ECHO MUGA scan ) FEV1 &gt; 60 % predict DLCO &gt; 45 % predict Negative HIV standard transplant workup Signed informed consent Are surgically biologically sterile willing practice acceptable birth control , follow : Females child bear potential must agree abstain sexual activity use medically approve contraceptive measure/regimen 3 month treatment period . Women child bear potential must negative serum urine pregnancy test time enrollment . Acceptable method birth control include oral contraceptive , intrauterine device ( IUD ) , transdermal/implanted injected contraceptive abstinence . Males must agree abstain sexual activity agree utilize medically approve contraception method 3 month treatment period A comorbid condition , view investigator , render patient high risk treatment complication Patients fail previous collection A residual acute medical condition result prior chemotherapy Acute infection Fever ( temp &gt; 38C/100.4F ) day start treatment Positive pregnancy test female patient Lactating female Patients child bear potential unwilling implement adequate birth control Patients whose actual body weight exceeds 150 % ideal body weight History ventricular arrhythmia Patients previously receive experimental therapy within 4 week enrol study currently enrol another experimental study mobilization phase Patients deterioration clinical status laboratory parameter time enrollment transplantation longer meet entry criterion may remove study discretion treat physician , principal investigator , sponsor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Plerixafor</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Hematopoietic Stem Cell Mobilization</keyword>
	<keyword>Transplantation , Autologous</keyword>
	<keyword>Receptors , CXCR4</keyword>
</DOC>